A comprehensive review published in World Journal of Pediatrics has delineated the distinct, stage-specific roles of chromodomain helicase DNA-binding (CHD) proteins in orchestrating cardiac development, providing a unifying framework that may explain the origins of many congenital heart defects and guide clinical genetic screening. The study synthesizes decades of evidence from human genetics, animal models, and stem-cell systems to assign specific cardiac functions to different CHD family members, revealing a clear division of labor.
CHD7, the gene most frequently mutated in CHARGE syndrome, shows the strongest link to cardiac development, playing a dominant role in building the heart's early structure. CHD3 and CHD4 act as "identity guardians," ensuring that heart cells commit to the correct fate during chamber formation. For CHD8, evidence suggests it regulates later ventricular growth and functional maturation. The authors propose three testable models—parallel, sequential, and compensatory—for how these remodelers might cooperate or back each other up, noting that direct proof of their coordinated action is lacking.
The findings have direct implications for clinical practice. For genetic screening, the study provides a clear priority: CHD7 for outflow‑tract defects, CHD4 for chamber‑patterning anomalies, and CHD8 for ventricular dysfunction. This prioritization can improve diagnostic efficiency. Therapeutically, while directly targeting remodelers is risky due to their broad expression, identifying their downstream pathways—such as those regulating cardiomyocyte proliferation or metabolism—may offer safer drug targets. Future studies combining time‑resolved multi‑omics and combinatorial genetics could uncover how these proteins coordinate across development, potentially paving the way for precise, temporally controlled epigenetic therapies.
The review, led by a team from China, is published in World Journal of Pediatrics (DOI: 10.1007/s12519-026-01049-y). The study was supported by grants from the National Key Research and Development Program of China and other funding bodies.
